Evidence map›Paper›PMID 40021783›Full record

ArticleScientific reports2025

Impact of LIN7A silencing on U87 cell invasion and its clinical significance in glioblastoma.

Xiaojuan Lyu, Yuxiang Shi, Daixu Wang, Xing Cao, Jipeng Guo, Guodong Huang, Lin Zhou, Mengxian Zhang, Zhen Dong

Abstract read
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Xiaojuan LyuDepartment of Oncology, Wuhan Centre Hospital, Wuhan, 430024, People's Republic of China.
Yuxiang ShiDepartment of Pathology, Wuhan Centre Hospital, Wuhan, 430024, People's Republic of China.
Daixu WangDepartment of Neurosurgery, Wuhan Centre Hospital, Wuhan, 430024, People's Republic of China.
Xing CaoDepartment of Oncology, Wuhan Centre Hospital, Wuhan, 430024, People's Republic of China.
Jipeng GuoDepartment of Oncology, Wuhan Centre Hospital, Wuhan, 430024, People's Republic of China.
Guodong HuangDepartment of Oncology, Wuhan Centre Hospital, Wuhan, 430024, People's Republic of China.
Lin ZhouDepartment of Histoembryology, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, People's Republic of China.
Mengxian ZhangDepartment of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, People's Republic of China.
Zhen DongDepartment of Neurosurgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, People's Republic of China. dongz@tjh.tjmu.edu.cn.

Funding

National Natural Science Foundation of China 81772680Wuhan Knowledge Innovation Special Dawn Plan Project 2022020801020538
6 · The paper itself

Abstract

Glioblastoma is highly aggressive and resistant to treatment, making it crucial to understand the regulatory mechanisms underlying its invasion. LIN7A, a polar protein, has been implicated in tumor cell migration and invasion, but its role in glioblastoma remains unclear. This study aimed to manipulate LIN7A gene expression in U87 cells, analyze its impact on invasion, and explore the potential mechanisms through which LIN7A regulates glioblastoma cell invasion. Lentiviral vectors were used to silence the LIN7A gene in U87 cells, selecting the most effective vector. LIN7A gene transcription, protein expression and localization were analyzed using RT-qPCR, Western blotting, and immunofluorescence. U87 cell invasion was assessed via real-time cell analysis and spheroid invasion assay, while MMP-2 and MMP-9 protease activities were measured using zymography. β-catenin protein levels and localization were evaluated through Western blotting and immunofluorescence. Expression of target genes in the β-catenin pathway was also measured. An orthotopic xenograft glioblastoma model in nude mice was established by intracranial implantation of U87 cells, with tumor growth monitored using immunofluorescence analysis of brain slices. The clinical significance of LIN7A expression was confirmed by comparing its levels in core and peripheral invading areas of glioblastoma and analyzing RNASeq data and clinical information from the Clinical Proteomic Tumor Analysis Consortium (CPTAC) GBM cohort. Transfection of U87 cells with a lentiviral vector led to decreased LIN7A levels and altered distribution patterns. Silencing the LIN7A gene increased U87 cell proliferation and invasiveness, reduced clonal formation ability, and enhanced MMP-2 and MMP-9 protease activity. It also resulted in a slight increase in cytoplasmic β-catenin content, although not statistically significant, but a significant increase in nuclear β-catenin accumulation and transcriptional activity of target genes in the pathway. Animal studies showed that LIN7A gene silencing caused U87 cells to transition from clumpy to invasive growth mode. LIN7A expression was significantly lower in the peripheral invading area compared to the core area in clinical samples of glioblastoma. Data mining of the CPTAC-GBM cohort revealed a strong association between LIN7A gene expression and survival time. Silencing LIN7A may promote U87 tumor cell invasion by disrupting intercellular junctions, altering cell polarity, and activating the β-catenin pathway. Further research is warranted to elucidate the role of LIN7A in glioblastoma cell invasion.

Indexed as

Brain NeoplasmsGene SilencingGlioblastomaAnimalsbeta CateninCell Line, TumorCell MovementCell ProliferationClinical RelevanceFemaleGene Expression Regulation, NeoplasticHumansMatrix Metalloproteinase 2Matrix Metalloproteinase 9MiceMice, Nudebeta CateninMatrix Metalloproteinase 2Matrix Metalloproteinase 9Cell invasionGlioblastomaLIN7Aβ-catenin

Identifiers

PMID40021783
PMCPMC11871311

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.